A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer

This study is testing whether adding trilaciclib — a drug that protects bone marrow cells from chemotherapy damage — to a standard chemotherapy regimen (mFOLFIRINOX) can reduce side effects and improve tolerability in patients with advanced pancreatic cancer. Trilaciclib works by temporarily pausing bone marrow activity during chemotherapy, which may protect blood cells from being damaged. **You may be eligible if...** - You are 18–75 years old - You have been diagnosed with pancreatic cancer confirmed by biopsy - You have not received any prior cancer treatment - You are in good health (ECOG 0–1) with adequate blood counts and organ function - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have had any prior systemic cancer treatment - You are pregnant or breastfeeding - You have substance abuse issues or psychological/social factors that would prevent you from participating Talk to your doctor to see if this trial is right for you.